PML News

Man on Ruxolitinib Develops PML

The drug ruxolitinib, used to treat intermediate or high risk myelofibrosis, has been associated with the development of progressive multifocal leukoencephalopathy (PML) in a 75-year-old man. It is not clear whether ruxolitinib caused the PML. (An association does not necessarily … read more

Preliminary Data Show Catching PML Early May Prevent Death

If patients with progressive multifocal leukoencephalopathy (PML) are diagnosed using magnetic resonance imaging before symptoms of the disease appear, their chances of survival are much greater than those of patients who are not diagnosed until their symptoms become evident, a … read more

New Drug for Hodgkin Lymphoma Has Been Fatal for PML Patients

ADCETRIS™ (generic name: brentuximab vedotin) is a new drug for treating Hodgkin Lymphoma (HL). On March 26, 2012, the makers of ADCETRIS announced that their clinical trial of ADCETRIS was quite successful. Three-quarters of the 100-plus HL patients treated with … read more

Positive JCV Test Found As New Risk Factor for PML

Testing positive for anti-JC virus (JCV) antibodies is a newly identified risk factor for a rare, but serious brain disorder associated with the drug Tysabri® (natalizumab), according to a U.S. Food and Drug Administration (FDA) Safety Announcement. Tysabri® is prescribed … read more

New Antibody Test Shown to Indicate PML Risk

If you test positive for having antibodies to the JC virus (JCV), you have an increased risk of getting progressive multifocal leukoencephalopathy (PML), according to a Food and Drug Administration (FDA) Safety Communication released Jan. 20, 2012. PML is a … read more

FDA Clears Phase II Trial of Drug to Treat JC Virus

The pharmaceutical company Inhibikase Therapeutics has received a green light from the U.S. Food and Drug Administration (FDA) to conduct a phase II clinical trial on a drug to treat the JC virus. The authorization to do the study is … read more

Elan Profits Nearly Triple Thanks to MS Drug Sales

Second-quarter profits for the Irish drug company Elan came close to tripling due to hefty sales of Tysabri®, its drug to treat multiple sclerosis. Elan co-markets the drug with Biogen.  Biogen issued higher than expected quarterly figures for Tysabri® in … read more

One In 25,000 Patients Treated with Rituxan Risk PML

An arthritis patient on the medication Rituxan™ faces a one in 25,000 chance of getting the deadly brain disease progressive multifocal leukoencephalopathy (PML), according to researchers at Washington University in St. Louis. David B. Clifford, M.D. and his co-workers published … read more

Contact Us

Schedule a free and confidential case review today.

* is a required field

Attorney Advertising:
Miller Legal LLP
700 12th Street, N.W. Suite 700
Washington, DC 20005